Powering Up: Next-Gen T-Cell Engager Combinations for Dual Sided Tumor Control
Time: 1:30 pm
day: Workshop A
Details:
Join this workshop to explore cutting-edge combination strategies that aim to boost the efficacy and durability of TCEs in oncological indications. As we move beyond single-agent approaches, the focus is on combining TCEs with other modalities, including ADCs, checkpoint inhibitors, radio therapies, and immune agonists, to unlock
greater tumor control. The session will cover how multi-mechanism combinations can overcome tumor heterogeneity, epitope spreading, and immune resistance, ensuring longer-lasting anti-tumor responses.
Discussion Points:
- Exploring the synergy between T cell engagers and standard therapies like checkpoint inhibitors, chemotherapy, and radiotherapy to enhance tumor elimination and epitope spreading
- Identifying next-gen combinations with immune agonists, co-stimulatory molecules, and targeted therapies to increase T cell activity and drive durable anti-tumor responses
- Evaluating novel approaches to combination strategies, balancing efficacy, safety, and immune activation for optimal therapeutic outcomes
